Common use of Development Milestone Payment Clause in Contracts

Development Milestone Payment. Dosing of first patient in a Phase 1 Clinical Study [*** ] Dosing of first patient in a Phase 2 Clinical Study [*** ] Dosing of first patient in a Phase 3 Clinical Study [*** ] Date of filing of BLA [*** ] Date of receipt of Regulatory Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] If a clinical milestone is achieved and any previous clinical milestone has not yet been achieved for any reason, notwithstanding anything herein to the contrary such previous milestone(s) shall be deemed to have been achieved and the corresponding Development Milestone Payment set forth in the table above shall be payable simultaneously with the Development Milestone Payment for the achievement of the subsequent Milestone. All Development Milestone Payments shall be non-refundable and noncreditable.

Development Milestone Payment. Dosing of first patient in a Phase 1 Clinical Study [*** ] Dosing of first patient in a Phase 2 Clinical Study Study* [*** ] Dosing of first patient in a Phase 3 Clinical Study [*** ] Date of filing of BLA [*** ] Date of receipt of Regulatory Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] If a clinical milestone is achieved and any previous clinical milestone has not yet been achieved for any reason, notwithstanding anything herein to the contrary such previous milestone(s) shall be deemed to have been achieved and the corresponding Development Milestone Payment set forth in the table above shall be payable simultaneously with the Development Milestone Payment for the achievement of the subsequent Milestone. All Development Milestone Payments shall be non-refundable and noncreditable.

Development Milestone Payment. Dosing of first patient in a Phase 1 Clinical Study [*** ] Dosing of first patient in a Phase 2 Clinical Study [*** ] Dosing of first patient in a Phase 3 Clinical Study [*** ] Date of filing of BLA [*** ] Date of receipt of Regulatory Approval in [***] the United States [*** ] Date of receipt of Regulatory Marketing Approval in [***] Major EU Market Country [*** ] Date of receipt of Regulatory Marketing Approval in [***] Japan [*** ] If a clinical milestone is achieved and any previous clinical milestone has not yet been achieved for any reason, notwithstanding anything herein to the contrary such previous milestone(s) shall be deemed to have been achieved and the corresponding Development Milestone Payment set forth in the table above shall be payable simultaneously with the Development Milestone Payment for the achievement of the subsequent Milestone. All Development Milestone Payments shall be non-refundable and noncreditable.

Development Milestone Payment. Dosing of first patient in a Phase 1 Clinical Study [*** ] Dosing of first patient in a Phase 2 Clinical Study Study* [*** ] Dosing of first patient in a Phase 3 Clinical Study [*** ] Date of filing of BLA [*** ] Date of receipt of Regulatory Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] Date of receipt of Regulatory Marketing Approval in [***] [*** ] 3 [***] “Cytotoxic Compound” [***] If a clinical milestone is achieved and any previous clinical milestone has not yet been achieved for any reason, notwithstanding anything herein to the contrary such previous milestone(s) shall be deemed to have been achieved and the corresponding Development Milestone Payment set forth in the table above shall be payable simultaneously with the Development Milestone Payment for the achievement of the subsequent Milestone. All Development Milestone Payments shall be non-refundable and noncreditable.

Development Milestone Payment. Dosing of first patient in a Phase 1 Clinical Study [*** ] $1,000,000 Dosing of first patient in a Phase 2 Clinical Study [*** ] $3,000,000 Dosing of first patient in a Phase 3 Clinical Study [*** *] Date of filing of BLA [*** *] Date of receipt of Regulatory Approval in the United States [***] [*** ] Date of receipt of Regulatory Marketing Approval in Major EU Market Country [***] [*** ] Date of receipt of Regulatory Marketing Approval in Japan [***] [*** ] If a clinical milestone is achieved and any previous clinical milestone has not yet been achieved for any reason, notwithstanding anything herein to the contrary such previous milestone(s) shall be deemed to have been achieved and the corresponding Development Milestone Payment set forth in the table above shall be payable simultaneously with the Development Milestone Payment for the achievement of the subsequent Milestone. All Development Milestone Payments shall be non-refundable and noncreditable. [***] Certain information contained herein has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.